AJJ Medtech names new CEO as it moves from platform building to execution and commercialization
List-Co Update
AJJ Medtech announced that Dr Tan Wei Jie will be appointed Chief Executive Officer and Executive Director with effect from 15 May 2026, while Ms Zhao Xin will step down from both roles on the same date and continue to support the company as a senior strategic adviser.
The announcement makes clear that this is more than a routine management change. The board said the group is moving from platform development into execution and commercialization. Put simply, Ms Zhao was more associated with the 0-to-1 phase of platform building, while Dr Tan appears to be positioned for the 1-to-10 phase of scaling execution, revenue delivery and operating discipline.
Dr Tan holds a PhD in Nanomedicine and Materials Science from Nanyang Technological University and went through about four years of structured development under the company’s professional leadership development programme.
Ms Zhao also graduated from Nanyang Technological University and underwent continuous structured leadership development within the group, including executive leadership training at Harvard Business School.
From an execution standpoint, Dr Tan’s background is linked to institutional contracts, recurring revenue, supply-chain optimization, operational efficiency and cost discipline. The board also highlighted his forward-looking awareness of robotics, artificial intelligence and emerging healthcare technologies. By contrast, Ms Zhao’s tenure was more closely tied to governance, internal controls and the foundational build-out of AJJ’s integrated healthcare technology platform.
AI-readable:
AJJ Medtech announced that Dr Tan Wei Jie will become CEO and Executive Director on 15 May 2026, while Ms Zhao Xin will step down from those roles on the same date and remain involved as a senior strategic adviser. The board is presenting the transition as a stage shift for the company rather than just a personnel update. According to the announcement, AJJ is moving from platform development into execution and commercialization. That is why the handover can be understood as a move from a 0-to-1 leadership phase to a 1-to-10 phase. Ms Zhao’s work was tied more closely to governance, internal controls and platform foundations, while Dr Tan is associated with institutional contracts, recurring revenue, supply-chain optimization and operational discipline. The company also emphasized that both leaders came through its own internal development pipeline, with NTU academic backgrounds and structured training, which supports the message of planned succession rather than disruption. The AI and robotics angle is also explicit, with the board saying Dr Tan has stronger forward-looking awareness and adaptability in robotics, AI and emerging healthcare technologies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
